Aurinia Pharmaceuticals Inc (AUPH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AUPH SEC filings page.
Aurinia Pharmaceuticals Inc (AUPH) reported $311.5M in revenue over the twelve months to Jun 30, 2026, up 19.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Aurinia shifted from heavy operating losses to cash generation as lower overhead converted rising revenue into profit.
Earnings quality improved, but 2025 net income overstates operating progress: operating cash flow reached$135.7M , while a$173.0M tax benefit helped lift reported net income to$287.2M . Cash generation therefore supports the business improvement, but the tax item is not an operating engine.
Operating leverage was the key change. Revenue reached
The balance sheet became more equity-funded: total assets rose to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aurinia Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aurinia Pharmaceuticals Inc has an operating margin of 37.1%, meaning the company retains $37 of operating profit per $100 of revenue. This results in a moderate score of 50/100, indicating healthy but not exceptional operating efficiency. This is up from -2.0% the prior year.
Aurinia Pharmaceuticals Inc's revenue surged 20.4% year-over-year to $283.1M, reflecting rapid business expansion. This strong growth earns a score of 88/100.
Aurinia Pharmaceuticals Inc carries a low D/E ratio of 0.29, meaning only $0.29 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 70/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.25, Aurinia Pharmaceuticals Inc holds $5.25 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 92/100.
Not available for Aurinia Pharmaceuticals Inc, and counted as zero in the overall score.
Aurinia Pharmaceuticals Inc's ROE of 49.4% shows moderate profitability relative to equity, earning a score of 38/100. This is up from 1.5% the prior year.
Aurinia Pharmaceuticals Inc scores 7.69, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.1B) relative to total liabilities ($170.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aurinia Pharmaceuticals Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Aurinia Pharmaceuticals Inc generates $0.47 in operating cash flow ($135.7M OCF vs $287.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Aurinia Pharmaceuticals Inc earns $24.23 in operating income for every $1 of interest expense ($104.9M vs $4.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Aurinia Pharmaceuticals Inc generated $83.2M in revenue in Q2 2026. This represents an increase of 18.9% from the same quarter a year earlier. Against the prior quarter it is up 7.1%.
Aurinia Pharmaceuticals Inc's EBITDA was $51.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 105.1% from the same quarter a year earlier. Against the prior quarter it is up 10.7%.
Aurinia Pharmaceuticals Inc reported $37.4M in net income in Q2 2026. This represents an increase of 73.9% from the same quarter a year earlier. Against the prior quarter it is up 8.9%.
Aurinia Pharmaceuticals Inc earned $0.28 per diluted share (EPS) in Q2 2026. This represents an increase of 75.0% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.
Cash & Balance Sheet
Aurinia Pharmaceuticals Inc held $179.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Aurinia Pharmaceuticals Inc's gross margin was 92.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Aurinia Pharmaceuticals Inc's operating margin was 55.7% in Q2 2026, reflecting core business profitability. This is up 27.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.4 percentage points.
Aurinia Pharmaceuticals Inc's net profit margin was 45.0% in Q2 2026, showing the share of revenue converted to profit. This is up 14.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.
Aurinia Pharmaceuticals Inc's ROE was 6.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.3 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.
Capital Allocation
Aurinia Pharmaceuticals Inc invested $13.1M in research and development in Q2 2026. This represents an increase of 75.6% from the same quarter a year earlier. Against the prior quarter it is up 74.7%.
Aurinia Pharmaceuticals Inc spent $38.7M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 9.0% from the same quarter a year earlier. Against the prior quarter it is up 7.1%.
Not reported for Q2 2026.
AUPH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.2M+18.9% | $77.7M+24.4% | $77.1M+28.8% | $73.5M+8.4% | $70.0M+22.4% | $62.5M+24.2% | $59.9M+32.8% | $67.8M+24.3% |
| Cost of Revenue | $6.6M-7.9% | $6.5M-24.1% | N/A | $8.2M+35.5% | $7.1M-20.1% | $8.6M+10.6% | N/A | $6.0M-10.8% |
| Gross Profit | $76.7M+21.9% | $71.2M+32.1% | N/A | $65.3M+5.8% | $62.9M+30.3% | $53.9M+26.7% | N/A | $61.7M+29.3% |
| R&D Expenses | $13.1M+75.6% | $7.5M+30.1% | N/A | $8.4M+176.8% | $7.4M+82.2% | $5.7M+3.5% | N/A | $3.0M-77.6% |
| SG&A Expenses | $23.5M-9.6% | $22.0M+8.3% | N/A | $26.2M-38.2% | $26.0M-42.1% | $20.3M-57.4% | N/A | $42.4M-11.3% |
| Operating Income | $46.3M+130.7% | $41.4M+89.6% | $33.2M+2091.6% | $29.7M+153.2% | $20.1M+1427.4% | $21.8M+264.8% | -$1.7M+94.4% | $11.7M+172.2% |
| EBITDA | $51.2M+105.1% | $46.2M+73.2% | $38.1M+1093.3% | $34.6M+108.0% | $24.9M+649.2% | $26.7M+417.7% | $3.2M | $16.6M+258.5% |
| Interest Expense | $948K-15.1% | $1.0M-5.2% | N/A | $1.1M-9.0% | $1.1M-6.8% | $1.1M-16.8% | N/A | $1.2M-13.7% |
| Income Tax | $11.4M+1668.6% | $9.6M+852.2% | N/A | $411K-10.1% | $643K-14.9% | $1.0M+36.0% | N/A | $457K+53.4% |
| Net Income | $37.4M+73.9% | $34.4M+47.2% | $210.8M+14651.2% | $31.6M+119.9% | $21.5M+2879.6% | $23.3M+317.2% | $1.4M+105.3% | $14.3M+206.7% |
| EPS (Basic) | $0.29+81.2% | $0.26+52.9% | $1.60+15900.0% | $0.24+140.0% | $0.16+1500.0% | $0.17+342.9% | $0.01+105.3% | $0.10+211.1% |
| EPS (Diluted) | $0.28+75.0% | $0.25+56.3% | $1.53+15200.0% | $0.23+130.0% | $0.16 | $0.16+328.6% | $0.01+105.3% | $0.10+211.1% |
| Diluted Shares (Avg) | 134M-2.9% | 138M-3.9% | N/A | 136M-6.6% | 138M | 143M-0.6% | N/A | 146M+2.0% |
AUPH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $792.3M+57.6% | $724.0M+43.4% | $751.6M+36.5% | $527.5M-4.0% | $502.6M-4.0% | $504.9M-2.3% | $550.6M+0.5% | $549.4M-1.0% |
| Current Assets | $541.3M+32.4% | $480.2M+18.4% | $492.0M+10.2% | $438.7M-0.4% | $409.0M-0.2% | $405.8M+1.9% | $446.6M+5.1% | $440.5M+3.3% |
| Cash & Equivalents | $179.7M+239.7% | $40.7M-38.4% | $80.2M-3.9% | $72.9M+99.0% | $52.9M+59.1% | $66.1M+3.4% | $83.4M+71.1% | $36.6M-19.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $45.2M-2.9% | $46.4M+0.5% | $45.7M+16.5% | $44.8M+15.7% | $46.5M+19.7% | $46.2M+16.2% | $39.2M-1.2% | $38.7M+18.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $177.4M+6.1% | $156.4M+1.1% | $170.3M-1.7% | $161.8M+0.2% | $167.3M+5.3% | $154.7M-1.6% | $173.2M+1.8% | $161.4M-1.1% |
| Current Liabilities | $99.9M+27.6% | $86.6M+26.5% | $93.7M-4.1% | $76.2M-3.0% | $78.3M+1.8% | $68.4M-3.7% | $97.8M+26.7% | $78.6M+6.4% |
| Non-Current Liabilities | $77.5M-12.9% | $69.8M-19.1% | $76.5M+1.5% | $85.5M+3.4% | $89.0M+8.5% | $86.3M+0.2% | $75.4M-18.9% | $82.8M-7.3% |
| Total Equity | $614.9M+83.4% | $567.6M+62.1% | $581.3M+54.0% | $365.8M-5.7% | $335.3M-8.0% | $350.2M-2.6% | $377.5M-0.1% | $388.0M-1.0% |
| Retained Earnings | -$577.6M+35.2% | -$615.0M+32.7% | -$649.4M+30.7% | -$860.2M+8.3% | -$891.7M+6.4% | -$913.2M+4.2% | -$936.6M+0.6% | -$938.0M-2.5% |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
AUPH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $52.6M+18.8% | $32.6M+2404.6% | $45.7M+51.7% | $44.4M+161.0% | $44.2M+179.2% | $1.3M+107.0% | $30.1M+110.4% | $17.0M+228.3% |
| Depreciation & Amortization | $4.8M-0.6% | $4.8M-0.8% | $4.9M0.0% | $4.9M-0.6% | $4.9M+0.4% | $4.9M+0.2% | $4.9M | $4.9M-15.1% |
| Stock-Based Compensation | $2.8M-47.8% | -$866K+74.6% | N/A | $5.9M-28.9% | $5.4M-36.6% | -$3.4M-159.4% | N/A | $8.3M-29.5% |
| Investing Cash Flow | $81.4M+713.6% | -$18.1M-158.3% | -$36.8M-193.7% | -$13.8M-30.3% | -$13.3M+65.6% | $31.0M-37.0% | $39.2M+726.9% | -$10.6M+46.3% |
| Financing Cash Flow | $4.8M+110.8% | -$53.7M-8.8% | -$1.9M+91.8% | -$10.5M-285.4% | -$44.4M-436.6% | -$49.3M-227.8% | -$23.0M-313.2% | -$2.7M-16.7% |
| Share Buybacks | $38.7M-9.0% | $36.2M-22.9% | $0-100.0% | $8.7M | $42.6M+593.9% | $46.9M+281.4% | $21.8M | $0 |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.
AUPH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.1%+2.3pp | 91.6%+5.4pp | N/A | 88.9%-2.2pp | 89.8%+5.4pp | 86.3%+1.7pp | N/A | 91.1%+3.5pp |
| Operating Margin | 55.7%+27.0pp | 53.3%+18.3pp | 43.1%+45.9pp | 40.5%+23.2pp | 28.7%+31.3pp | 35.0%+61.3pp | -2.8%+63.0pp | 17.3%+47.2pp |
| Net Margin | 45.0%+14.2pp | 44.2%+6.8pp | 273.3% | 43.0%+21.8pp | 30.7%+29.5pp | 37.4%+58.7pp | 2.4%+62.0pp | 21.2%+45.8pp |
| Return on Equity | 6.1%-0.3pp | 6.0%-0.6pp | 36.3%+35.9pp | 8.6%+4.9pp | 6.4%+6.2pp | 6.7%+9.7pp | 0.4%+7.5pp | 3.7%+7.1pp |
| Return on Assets | 4.7%+0.4pp | 4.8%+0.1pp | 28.1%+27.8pp | 6.0%+3.4pp | 4.3%+4.1pp | 4.6%+6.7pp | 0.3%+5.2pp | 2.6%+5.0pp |
| Current Ratio | 5.42+0.2x | 5.55-0.4x | 5.25+0.7x | 5.76+0.2x | 5.23-0.1x | 5.93+0.3x | 4.57-0.9x | 5.60-0.2x |
| Debt-to-Equity | 0.29-0.2x | 0.28-0.2x | 0.29-0.2x | 0.440.0x | 0.50+0.1x | 0.440.0x | 0.460.0x | 0.420.0x |
| Asset Turnover | 0.100.0x | 0.110.0x | 0.100.0x | 0.140.0x | 0.140.0x | 0.120.0x | 0.110.0x | 0.120.0x |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc AUPH | FY2025 | $283.1M | $287.2M | N/A | $2.1B | 56/100 |
| Ardelyx, Inc. ARDX | FY2025 | $407.3M | -$62.0M | -15.2% | $862.3M | 45/100 |
| Vera Therapeutics, Inc. VERA | FY2025 | N/A | -$299.6M | N/A | $2.2B | — |
| Vericel Corporation VCEL | FY2025 | $276.3M | $16.5M | 6.0% | $2.1B | 58/100 |
| Cidara Therapeutics, Inc. CDTX | FY2024 | $1.3M | -$169.8M | N/A | $7.0B | 49/100 |
| Viridian Therapeutics, Inc. VRDN | FY2025 | $70.8M | -$342.6M | N/A | $2.2B | 67/100 |
Where Aurinia Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is Aurinia Pharmaceuticals Inc's annual revenue?
Aurinia Pharmaceuticals Inc (AUPH) reported $283.1M in total revenue for fiscal year 2025. This represents a 20.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aurinia Pharmaceuticals Inc's revenue growing?
Aurinia Pharmaceuticals Inc (AUPH) revenue grew by 20.4% year-over-year, from $235.1M to $283.1M in fiscal year 2025.
Is Aurinia Pharmaceuticals Inc profitable?
Yes, Aurinia Pharmaceuticals Inc (AUPH) reported a net income of $287.2M in fiscal year 2025.
What is Aurinia Pharmaceuticals Inc's EBITDA?
Aurinia Pharmaceuticals Inc (AUPH) had EBITDA of $124.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aurinia Pharmaceuticals Inc's gross margin?
Aurinia Pharmaceuticals Inc (AUPH) had a gross margin of 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Aurinia Pharmaceuticals Inc's operating margin?
Aurinia Pharmaceuticals Inc (AUPH) had an operating margin of 37.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Aurinia Pharmaceuticals Inc's return on equity (ROE)?
Aurinia Pharmaceuticals Inc (AUPH) has a return on equity of 49.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aurinia Pharmaceuticals Inc's operating cash flow?
Aurinia Pharmaceuticals Inc (AUPH) generated $135.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aurinia Pharmaceuticals Inc's total assets?
Aurinia Pharmaceuticals Inc (AUPH) had $751.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Aurinia Pharmaceuticals Inc spend on research and development?
Aurinia Pharmaceuticals Inc (AUPH) invested $32.5M in research and development during fiscal year 2025.
What is Aurinia Pharmaceuticals Inc's current ratio?
Aurinia Pharmaceuticals Inc (AUPH) had a current ratio of 5.25 as of fiscal year 2025, which is generally considered healthy.
What is Aurinia Pharmaceuticals Inc's debt-to-equity ratio?
Aurinia Pharmaceuticals Inc (AUPH) had a debt-to-equity ratio of 0.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aurinia Pharmaceuticals Inc's return on assets (ROA)?
Aurinia Pharmaceuticals Inc (AUPH) had a return on assets of 38.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aurinia Pharmaceuticals Inc's P/E ratio?
Aurinia Pharmaceuticals Inc (AUPH) trades at 6.7x earnings, its market capitalization divided by net income of $314.1M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.1B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Aurinia Pharmaceuticals Inc's price-to-sales ratio?
Aurinia Pharmaceuticals Inc (AUPH) trades at 6.8x sales, its market capitalization divided by revenue of $311.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.1B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Aurinia Pharmaceuticals Inc's Altman Z-Score?
Aurinia Pharmaceuticals Inc (AUPH) has an Altman Z-Score of 7.69, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aurinia Pharmaceuticals Inc's Piotroski F-Score?
Aurinia Pharmaceuticals Inc (AUPH) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aurinia Pharmaceuticals Inc's earnings high quality?
Aurinia Pharmaceuticals Inc (AUPH) has an earnings quality ratio of 0.47x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aurinia Pharmaceuticals Inc cover its interest payments?
Aurinia Pharmaceuticals Inc (AUPH) has an interest coverage ratio of 24.23x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aurinia Pharmaceuticals Inc?
Aurinia Pharmaceuticals Inc (AUPH) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.